Orchestra BioMed Holdings, Inc.·4

Feb 13, 5:01 PM ET

Taylor Andrew Lawrence 4

4 · Orchestra BioMed Holdings, Inc. · Filed Feb 13, 2026

Research Summary

AI-generated summary of this filing

Updated

Orchestra BioMed (OBIO) CFO Taylor Andrew Lawrence Receives Award

What Happened

  • Taylor Andrew Lawrence, Chief Financial Officer of Orchestra BioMed (OBIO), was granted 181,000 restricted stock units (RSUs) on 2026-02-12. The award was reported on Form 4 as an acquisition via grant (code A) at $0.00 per share (no cash paid at grant). Each RSU represents a contingent right to one share of common stock upon vesting.

Key Details

  • Transaction date: 2026-02-12; Filing date: 2026-02-13 (filed timely).
  • Grant amount and price: 181,000 RSUs at $0.00 (award/grant).
  • Vesting: Four equal tranches of 25% (45,250 RSUs each) vest over time per footnote: 18, 24, 30 and 36 months after the issue date (Feb 12, 2026), subject to continuous service.
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Transaction code: A = Award/Grant of RSUs.

Context

  • RSUs are a form of compensation/retention award, not an immediate purchase or sale. No shares are delivered until each tranche vests, and value to the holder depends on Orchestra BioMed's share price at vesting.
  • Such grants are common for executives and do not by themselves indicate a buy/sell signal; they reflect company compensation practices and retention incentives.

Insider Transaction Report

Form 4
Period: 2026-02-12
Taylor Andrew Lawrence
Chief Financial Officer
Transactions
  • Award

    Common Stock, par value $0.0001 per share

    [F1]
    2026-02-12+181,000632,493 total
Footnotes (1)
  • [F1]Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 25% of the shares will vest 18 months after February 12, 2026 (the "Issue Date"), (ii) 25% of the shares will vest 24 months after the Issue Date, (iii) 25% of the shares will vest 30 months after the Issue Date and (iv) 25% of the shares will vest 36 months after the Issue Date, subject to the Reporting Person's continuous service through such dates.
Signature
/s/ Andrew Taylor|2026-02-13

Documents

1 file
  • 4
    tm266316-2_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT